Kamada (KMDA) said Wednesday it was awarded a contract with an unnamed international organization to supply Kamrab and Varizig in Latin America for the 2025-2027 period.
Revenue under the three-year contract is expected to be about $25 million, the company said.
Kamrab is indicated for the prevention of rabies infection after contact with rabid or possibly rabid animals, while Varizig is a varicella drug for post-exposure prophylaxis in high-risk individuals, Kamada said.
The company's shares were rising past 5% in recent trading.
Price: 7.48, Change: +0.40, Percent Change: +5.64
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.